The Bundibugyo strain of Ebola had caused only two recognized outbreaks in the four decades since it was first identified, recording a combined total of fewer than 250 cases across Uganda and the DRC. The current Ebola virus outbreak has already surpassed 4,381 confirmed cases in less than three months, making that historical baseline look almost unrecognizable by comparison.
The DRC Ministry of Health confirmed the outbreak on May 15, 2026, in Ituri Province in the country’s northeast. Early laboratory results were delayed in part because the Bundibugyo strain is a different variant from the one that caused the 2014 outbreak, and initial tests designed for that earlier strain returned negative results, complicating detection.
By the time the global health community registered the full scale of the crisis, the virus had already embedded itself across multiple provinces. A total of 4,381 Ebola cases across five provinces of the DRC were confirmed as of August 11, 2026, including more than 2,000 deaths, according to Al Jazeera. The outbreak is the fastest-growing on record in the Central African country and is second in size only to the West African outbreak of 2014 to 2016, during which 11,310 people died. The 2014 West Africa epidemic – the largest in Ebola’s history – took 28 months to fully unfold. The current outbreak has approached that historical scale in under a quarter of that time.
Dr. David Wohl, a professor of medicine in the Division of Infectious Diseases at the University of North Carolina at Chapel Hill, has described the outbreak’s trajectory as a “perfect storm” of adverse conditions – dense urban populations, active armed conflict, strained healthcare systems, and an absence of approved medical countermeasures for this specific viral strain. Speaking to NC Newsline, he said: “There’s quite a bit that we’re finding out, and none of it is really good news. There has been an ongoing outbreak of Ebola with a strain called Bundibugyo.”
What makes the Bundibugyo Ebola virus outbreak different
The outbreak is caused by the Bundibugyo strain of the Ebola virus, a rarer species than the Zaire strain responsible for the 2014 to 2016 West Africa epidemic. That genetic difference has serious practical implications. Diagnostic tools calibrated to the Zaire strain initially failed to flag early Bundibugyo cases, allowing the virus to spread further before containment measures could be organized. The vaccines and antiviral therapies successfully deployed during the 2014 crisis – specifically Ervebo and the monoclonal antibody treatment mAb114 – were developed against the Zaire strain and carry no approval for Bundibugyo virus disease.
No approved treatment or vaccine currently exists for the Bundibugyo strain of Ebola responsible for the DRC’s outbreak. As of July 30, 2026, the confirmed case fatality ratio stood at 44%, meaning nearly one in two people diagnosed with the disease has died from it. That figure is consistent with the known lethality of previous Bundibugyo outbreaks, but the scale of transmission in 2026 makes the absolute death toll without precedent for this strain.
The Bundibugyo virus disease outbreak in the DRC is intensifying, with sustained transmission and continued increases in reported cases and deaths. Initially confined to the Mongbwalu health zone in Ituri Province, the outbreak has expanded over two months to five provinces – Ituri, North Kivu, South Kivu, Haut-Uélé, and Tshopo – now affecting 49 health zones. Eighty-seven percent of cases are in Ituri Province, the epicenter of the outbreak, with 11 percent in neighboring North Kivu.
The ECDC is tracking the situation in real time, noting that the week ending August 11, 2026, saw 117 new confirmed cases and 67 deaths in a single 24-hour reporting period.
Why the outbreak has proven so difficult to contain
The outbreak is occurring in areas affected by insecurity, population displacement, mining-related population movement, and frequent cross-border travel, all of which increase the risk of further transmission. The DRC’s eastern provinces have been the site of sustained armed conflict for decades, and that conflict has significantly restricted humanitarian access and medical care during the epidemic.
The response has also been complicated by strikes by unpaid health workers, misinformation, and cultural traditions – including intimate family burials of those killed by the virus, which can increase the risk of further transmission. Ebola spreads most efficiently in the period immediately after death, when viral loads in a body are at their peak. Traditional burial practices that involve washing or touching the deceased have historically been associated with cluster infections in previous outbreaks.
Dr. Wohl has spoken about the changing state of global health infrastructure, telling North Carolina Health News in May 2026: “I see that the opportunities – for collaboration, for data sharing, for really being around the same table – are no longer the same as they were before. That worries me. I think when you have a global threat like this, you really do want trust and good relationships.” He added: “I worry that we don’t have that to the same degree we did before.”
The WHO has noted that surveillance gaps in conflict-affected eastern DRC make it difficult to ascertain the true geographic spread of the epidemic or the full number of infections, meaning official case counts may understate the actual toll. The outbreak has also crossed DRC’s borders, with cases confirmed in Uganda – though Uganda subsequently declared its outbreak over on July 28, 2026 – and at least one imported case confirmed in another country.
What the risk looks like for Americans
As of August 12, 2026, no cases of Ebola disease have been confirmed in the United States, and the overall risk to the American public and travelers remains low.
The biological basis for that low risk comes down to how the virus spreads. According to the CDC, the likelihood of Ebola spreading to the United States is considered very low, and if a case were diagnosed in the US, the risk of wider spread is also low due to the strength of the American public health system and infection control measures. The ECDC confirms that Ebola is not airborne – transmission requires direct contact with the bodily fluids of a symptomatic or deceased individual.
The historical precedent from the last major outbreak supports this assessment. The 2014 West Africa outbreak, caused by the Zaire strain, generated more than 28,000 cases across Guinea, Liberia, and Sierra Leone, yet only four Ebola cases were diagnosed in the US – two imported cases and two nurses who contracted the virus while caring for a patient in Dallas, according to the CDC.
Dr. Wohl has been direct about what this means for the average American. Better public health systems, healthcare infrastructure, hygiene standards, and access to care create a fundamentally different environment from the one currently facing communities in eastern DRC. For Americans who develop fever or headache, the more immediate domestic threats – including influenza and RSV – remain far more statistically probable than Ebola.
The populations who face genuine elevated risk are healthcare workers and humanitarian aid personnel traveling to affected regions. Contact with patients in clinical settings – particularly without proper personal protective equipment – accounts for the majority of healthcare worker infections in every recorded Ebola outbreak.
The race to build a Bundibugyo vaccine
Bundibugyo had caused only two known prior outbreaks before 2026 – one in Uganda in 2007 – 2008 and one in the DRC in 2012 – with a combined case count of roughly 200 people. There was no commercial incentive to develop a strain-specific vaccine, and none existed when this outbreak began.
Oxford University initiated the first clinical trial for the Bundibugyo strain on July 13, 2026. CEPI is backing Oxford’s candidate, based on the ChAdOx viral-vector platform and manufactured by the Serum Institute of India. The trial is testing the safety of the ChAdOx1 BDBV vaccine and the immune response it triggers in 50 healthy adults between 18 and 55.
Moderna followed shortly after. The company dosed the first participants in a Phase 1 clinical trial of its investigational vaccine mRNA-1469 on August 3 – 4, 2026, designed to prevent infection caused by Bundibugyo ebolavirus. The study, authorized by Health Canada, is being conducted at three sites across Canada and will evaluate the safety, tolerability, and immune response of the vaccine in approximately 80 healthy adults. Developed using Moderna’s mRNA platform – the same technology used to develop COVID-19 vaccines – mRNA-1469 builds on the company’s ongoing research in filoviruses, the family of pathogens that includes Ebola.
The program sits within Moderna’s partnership with CEPI, which has committed up to US$50 million to support preclinical development and Phase 1 clinical testing of mRNA-1469, according to CEPI. Should mRNA-1469 ultimately receive approval, Moderna has pledged to supply a minimum of 500,000 doses to low- and middle-income countries at preferential pricing as part of its arrangement with CEPI.
A Phase 1 trial tests primarily for safety and immune response in healthy volunteers – it does not confirm efficacy in infected patients, and it is not the same as having a deployable vaccine. The WHO has emphasized that no vaccine or specific treatment yet exists for the Bundibugyo species and that work on promising candidates is ongoing.
The global infrastructure question
WHO declaration on May 17, 2026, designated the outbreak a Public Health Emergency of International Concern – the organization’s highest-level alert designation, reserved for events that constitute a risk beyond the borders of the affected state.
The global health infrastructure – and the relationships among the agencies and nations that shaped responses to previous global health emergencies – has changed significantly, as has the role of the US CDC. Dr. Wohl, whose work on emerging infectious diseases spans multiple outbreak responses across West and Central Africa, has been specific about what that change means in practice: fewer opportunities for real-time data sharing, reduced coordination between international and domestic health authorities, and weaker institutional relationships at precisely the moment they are most needed.
The CDC’s current situation summary acknowledges the agency is actively responding, but changes in US engagement with WHO have complicated data-sharing arrangements that previously allowed coordination during outbreak responses. That gap matters most not for Americans at home but for the international responders attempting to contain a rapidly expanding outbreak in one of the world’s most challenging operating environments.
As CEPI CEO Dr. Richard Hatchett stated in a June 2026 press release: “With Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease.” Vaccine candidates moving through Phase 1 trials in August 2026 must still clear safety reviews, demonstrate efficacy, achieve emergency use authorization, and reach affected communities in the DRC – a sequence that, under favorable conditions, takes many months.
Key takeaways
The 2026 Ebola virus outbreak in the DRC is the fastest-growing in DRC history, the second-largest in Ebola’s recorded history, and the first major outbreak caused by the Bundibugyo strain for which no approved vaccine or treatment currently exists. Over 2,000 people have died in under three months, and the outbreak continues to expand across five provinces with no clear inflection point in the case trajectory.
For Americans, the personal risk of infection remains very low. The virus does not travel through the air, and the US public health system’s capacity to identify, isolate, and contain any imported case is well-established by the 2014 precedent. The populations who carry genuine elevated risk are humanitarian workers and healthcare providers working in or returning from affected regions in the DRC. Clinicians seeing patients with recent travel to those areas should include Bundibugyo virus disease in their differential if symptoms match: fever, generalized body pain, weakness, vomiting, and in some cases bleeding.
The absence of Bundibugyo-specific medical countermeasures prior to 2026 was a predictable consequence of underinvestment in vaccines for rare, geographically isolated diseases. Two vaccine candidates are now in Phase 1 trials. Whether they reach the people most at risk in time depends on the speed of regulatory review, manufacturing scale-up, and the willingness of international actors to sustain the resource commitments that outbreak containment requires.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.